Produtos Naturais em Fase Avançada de Testes Clínicos no Tratamento contra o Câncer

M. V. N. Souza; A. C. Pinheiro; M. L. Ferreira; R. S. B. Gonçalves; Camilo H. da C. Lima

doi:10.32712/2446-4775.2007.72

Produtos Naturais em Fase Avançada de Testes Clínicos no Tratamento contra o Câncer

v. 3 n. 02 (2007)
25-42
18/10/2013
01/06/2007
https://doi.org/10.32712/2446-4775.2007.72

M. V. N. Souza
A. C. Pinheiro
M. L. Ferreira
R. S. B. Gonçalves
Camilo H. da C. Lima

Palavras-chave

Antineoplásica

Fármacos Anticâncer

Desenvolvimento de Fármacos

Resumo

Atualmente, os produtos naturais representam uma inestimável fonte de substâncias químicas tendo um importante papel no tratamento do câncer. Devido à importância da natureza como fonte de novos candidatos a fármacos no tratamento contra o câncer, o objetivo dessa revisão é enfocar os produtos naturais, que estão em fase avançada de testes clínicos e dentre em breve poderão ser introduzidos no mercado no combate ao câncer.

Referências

AHN, Y. M.; VOGETI, L.; LIU, C.; SANTHAPURAM, H. K. R.; WHITE, J. M.; VASANDANI, V.; MITSCHER, L. A.; LUSHINGTON, G. H.; HANSON, P. R.; POWELL, D. R.; HIMES, R. H.; ROBY, K. F.; YE, Q.; GEORG, G. Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues. Bioorganic & Medicinal Chemistry, v.15, n.2, p.702-713, 2007.
ALBERTS, B.; BRAY, D.; LEWIS, J.; RAFF, M.; ROBERTS, K.; WATSON, J. D. Molecular biology of the cell, Garland Publishing; New York & London; 1994.
ALBERTS, M. W.; WILLIAMS, R.T.; BROWN, E. J.; TANAKA, A.; HALL, F. L.; SCHREIBER, S. L. FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line. Journal of Biological chemistry, v.268, n.30, p.22825-22829, 1993.
ALCARO, S.; MARINO, T.; ORTUSO, F.; RUSSO, N. Conformational behavior of antineoplastic peptides Dolastatin 10 and Dolastatin 15 from Monte Carlo and molecular dynamics simulations. International Journal of Quantum Chemistry, v.107, n.2, p.318-325, 2007.
BAI, X.C.; LIU, AN-LING, LUO, SHEN-QIU. Phospholipase C is required for survival in heat stress: involvement of protein kinase C-dependent Bcl-2 phosphorylation. Journal of Biochemistry, v.131, n.2, p.207-212, 2002.
BAGATELL, R.; BELIAKOFF, J.; DAVID, C. L.; MARRON, M. T.; WHITESELL, L. Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin. International Journal of Cancer, v.113, n.2, p.179-188, 2005.
BEDIN, M.; GABEN, A. M.; SAUCIER, C.; MESTER, J. Geldanamycin, an inhibitor of the chaperone activity of HSP90, induces MAPK-independent cell cycle arrest. International Journal of Cancer, v.109, n.5, p.643-652, 2004.
BERGMANN, W.; BURKE, D. C. Contributions to the study of marine products. The nucleosides of sponges. Journal of Organic Chemistry, v.20, n.11, p.1501-1507, 1955.
BEUMER, J. H.; RADEMAKER-LAKHAI, J. M.; ROSING, H.; HILLEBRAND, M. J. X.; BOSCH, T. M.; LAZARO, L. L.; SCHELLENS, J. H. M.; BEIJNEN, J. H. Metabolism of trabectedin (ET-743, Yondelisâ„¢) in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, v.59, n.6, p.825-837, 2007.
BRANDON, E. F. A.; SPARIDANS, R. W.; OOIJEN, R. D.; MEIJERMAN, I.; LAZARO, L. L.; MANZANARES, I.; BEIJNEN, J. H.; SCHELLENS, J. H. M. In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anticancer drug. Investigational New Drugs, v.25, n.1, p.9-19, 2007.
CHEN, X.; CHEN, J.; ZHU, J. Synthetic studies on ecteinascidin 743 (Et 743): asymmetric synthesis of a highly oxygenated tetrahydroisoquinoline via a key phenolic Mannich reaction. Synthesis, n.23, p.4081-4086, 2006.
CALABRESI, P.; CHABNER, B. A. Chemotherapy of neoplasic diseases, Em Goodman e Gilman´s: the pharmacological basis of therapeutical, MacGraw-Hill; New York; 2001.
CAUBERT, V.; MASSE, J.; RETAILLEAU, P.; LANGLOIS, N. Stereoselective formal synthesis of the potent proteasome inhibitor: salinosporamide A. Tetrahedron Letters, v.48, n.3, p.381-384, 2007.
CHEN, W.; SHAO, X.; MOELLERING, R.; WENNERSTEN, C.; REGEN, S. L.; Bioconjugate Chemistry, v.17, n.6, p.1582-1591, 2006.
CHLADE-BARTUSIAK, K.; STEMBALSKA-KOZLOWSKA, A.; BERNADY, M.; KUDYBA, M.; SASIADEK, M. Analysis of adaptive response to bleomycin and mitomycin. Mutation Research, Genetic Toxicology and Environmental Mutagenesis, v.513, n.1, p.75-81, 2002.
CHO, J. J.; KIM, Y. T. Sharks: A Potential Source of Antiangiogenic Factors and Tumor Treatments. Marine Biotechnology, v.4, n.6, p.521-525, 2002.
CRAGG, G. M.; NEWMAN, D. J. A Tale of Two Tumor Targets: Topoisomerase I and Tubulin. The Wall and Wani Contribution to Cancer Chemotherapy. Journal of Natural Products, v.67, n.2, p.232-244, 2004.
CUENDET, M.; PEZZUTO, J. M. Antitumor Activity of Bruceantin: An Old Drug with New Promise. Journal of Natural Products, v.67, n.2, p.269-272, 2004.
DE VITA JR., V. T.; HELLMAN, S.; ROSENBERG, S. A. Cancer: Principles of Oncology, LippincottRaven Publishers; Phifadelphia, 1997.
DONIA, M.; HAMANN, M. T. Marine natural products and their potential applications as anti-infective agents. Lancet Infectious Diseases, v.3, n.6, p.338-348, 2003.
ERBA, E.; BASSANO, L.; DI LIBERTI, G. Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine. British Journal of Cancer, v.86, n.9, p.1510-1517, 2002.
ERBA, E.; BERGAMASCHI, D.; BASSANO, L. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. European Journal of Cancer, v.37, n.1, p.97-105, 2001.
GARCÍA-FERNÁNDEZ, L.F.; LOSADA, A.; ALCALDE, V. Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C. Oncogene, v.21, n.49, p.7533-7544, 2002.
GARCIA, C. R.; SUPKO, J.G.; MANOLA, J. Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy. Journal of Clinical Oncology, v.22, n.8, p.1480-1490, 2004.
GRACIA, C.; ISIDRO-LLOBET, A.; CRUZ, L. J.; ACOSTA, G. A.; ALVAREZ, M.; CUEVAS, C.; GIRALT, E.; ALBERICIO, F. Convergent Approaches for the Synthesis of the Antitumoral Peptide, Kahalalide F. Study of Orthogonal Protecting Groups. Journal of Organic Chemistry, v.71, n.19, p.7196-7204, 2006.
GSCHWEND, J.E. Bryostatin 1 induces prolonged activation of extracellular regulated protein kinases in and apoptosis of LNCaP human prostate cancer cells overexpressing protein kinase C. Molecular Pharmacology, v.57, n.6, p.1224-1234, 2000.
HITOTSUYANAGI, Y.; KIM, I. H.; HASUDA, T.; YAMAUCHI, Y.; TAKEYA, K. A structure-activity relationship study of brusatol, an antitumor quassinoid. Tetrahedron, v.62, n.17, p.4262-4271, 2006.
INCA: Instituto Nacional de Câncer. http://www.inca.gov.br/situacao/arquivos/ocorrencia_magnitude_cancerbrasil.pdf; Acessado em 15/04/2007a.
INCA: Instituto Nacional de Câncer. http://www.inca.gov.br/conteudo_view.asp?id=101, Acessado em 15/04/2007b.
JULSING, M. K.; KOULMAN, A.; WOERDENBAG, H. J.; QUAX, W. J.; KAYSER, O. Combinatorial biosynthesis of medicinal plant secondary metabolites. Biomolecular Engineering, v.23, n.6, p.265-279, 2006.
KECK, G. E.; WELCH, D. S.; POUDEL, Y. B. Synthetic studies toward bryostatin 1: preparation of a C1-C16 fragment by pyran annulation. Tetrahedron Letters, v.47, n.47, p.8267-8270, 2006.
KLINDLEN, H. L. Phase II study of flavopiridol in patients with advanced colorectal cancer. Annals of Oncology, v.14, p.1270-1273, 2003.
KOUROUKIS, C. T.; BELCH, A.; CRUMP, M.; EISENHAUER, E.; GASCOYNE, R. D.; MEYER, R.; LOHMANN, R.; LOPEZ, P.; POWERS, J.; TURNER, R.; CONNORS, J. M. Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, v.21, n.9, p.1740-1745, 2003.
KUPCHAN, S. M.; BRITTON, R. W.; ZIEGLER, M. F.; SIGEL, C. W. Bruceantin, a new potent anti- leukemic simaroubolide from Brucea antidysenterica. Journal of Organic Chemistry,v.38, n.1, p.178-179, 1973.
LE CESNE, L.; BLAY, J.Y.; JUDSON, I. Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organization for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial. Journal of Clinical Oncology, v.23, n.3, p.576-584, 2005.
LIN, C. M. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Molecular Pharmacology, v.34, n.2, p.200-208, 1988.
MADDEN, T.; TRAN, H. T.; BECK, D.; HUIE, R.; NEWMAN, R. A.; PUSZTAI, L.; WRIGHT, J. J.; ABBRUZZESE, J. L. Novel Marine-derived Anticancer Agents: A Phase I Clinical, Pharmacological, and Pharmacodynamic Study of Dolastatin 10 (NSC 376128) in Patients with Advanced Solid Tumors. Clinical Cancer Research, v.6, n.4, p.1293-1301, 2000.
MANN, J. Natural products in cancer chemotherapy: past, present and future. Nature Reviews Cancer, v.2, n.2, 143-148, 2002.
MINUZZO, M.; MARCHINI, S.; BROGGINI, M.; FAIRCLOTH, G.T.; D’INCALCI, M.; MANTOVANI, R. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proceedings of the National Academy of Sciences of the United States of America, v.97, n.12, p. 6780-6784, 2000.
NERI, B.; PANTALEO, P.; GIOMMONI, E.; GRIFONI, R.; PAOLETTI, C.; ROTELLA, V.; PANTALONE, D.; TADDEI, A.; MERCATELLI, A.; TONELLI, P. Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study. British Journal of Cancer, v.96, p.1043-1046, 2007.
NEWMAN, D. J.; CRAGG, G. M.; SNADER, K. M. Natural Products as Sources of New Drugs over the Period 1981-2002. Journal of Natural Products, v.66, n.7, p.1022-1037, 2003.
NOVAK, N.; GERDIN, S.; BEROVIC, M. Increased lovastatin formation by Aspergillus terreus using repeated fed-batch process. Biotechnology Letters, v.19, n.10, p.947-948, 1997.
POMMIER, Y. Topoisomerase I inhibitors: camptothecins and beyond. Nature Reviews Cancer, v.6, n.10, p.789-802, 2006.
RADEMAKER-LAKHAI, J.; HORENBLAS, S.; MEINHARDT, W. Phase I Clinical and Pharmacokinetic Study of Kahalalide F in Patients with Advanced Androgen Refractory Prostate Cancer. Clinical Cancer Research, v.11, n.5, p.1854-1862, 2005.
RITU, B.; UMA, S.; NANDANA, S.; MONICA, J.; PAMITA, A.; MANPREET, K.; KUMAR, B. S.; GIRJESH, G. Structure of daunomycin complexed to dTGATCA by two-dimensional nuclear magnetic resonance spectroscopy. European Journal of Medicinal Chemistry, v.41, n.1, p.27-39, 2006.
ROBERT, H.; FELING, G. O.; BUCHANAN, T. J.; MINCER, C. A.; KAUFFMAN, P. R.; FENICAL, W. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angewandte Chemie, International Edition, v.42, n.3, p.355-357, 2003.
ROCHA, A. B.; LOPES, R. M.; SCHWARTSMANN, G. Natural products in anticancer therapy. Current Opinion in Pharmacology, v.1, n.4, p. 364-369,
SCHULTE, T. W.; NECKERS, L. M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemotherapy and Pharmacology, v.42, n.4, p.273-279, 1998.
SENDEROWICZ, A. M. Flavopiridol: the First Cyclin-Dependent Kinase Inhibitor in Human Clinical Trials. Investigational New Drugs, v.17, n.3,
p.313-320, 1999.
SOLAR, P.; HORVATH, V.; KLEBAN, J.; KOVAL, J.; SOLAROVA, Z.; KOZUBIK, A.; FEODOROCKO, P. Hsp90 inhibitor Geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin. Neoplasma, v.54, n.2, p.127-130, 2007.
SPANO, A.; MONACO, G.; BARNI, S.; SCIOLA, L. Expression of cell kinetics and death during monocyte-macrophage differentiation: Effects of actinomycin D and vinblastine treatments. Histochemistry and Cell Biology, v.127, n.1, p.79-94, 2007.
SOUZA, M. V. N. New natural products able to act on the stabilization of microtubules, an important target against cancer. Química Nova, v.27,
n.2, p.308-312, 2004.
STROSBERG, J. R.; KVOLS, L. K. A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours. Expert Opinion on Investigational Drugs, v.16, n.2, p.219-224, 2007.
SUN, M.; ALKON, D. L. Bryostatin-1: Pharmacology and Therapeutic Potential as a CNS Drug. CNS Drug Reviews, v.12, n.1, p.1-8, 2006.
TEDESCHI, A.; MONTILLO, M.; STROCCHI, E.; CAFRO, A. M.; TRESOLDI, E.; INTROPIDO, L.; NICHELATTI, M.; MARBELLO, L.; BARATE, C.; CAMAGGI, C. M.; MORRA, E. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Cancer Chemotherapy and Pharmacology, v.59, n.6, p.771-779, 2007.
THUN, M. J.; JEMAL, A.; SIEGEL, R.; WARD, E.; MURRAY, T.; XU, J.; SMIGAL, C. Cancer Statistics. CA-A Cancer Journal for Clinicians, v.56, n.2, p.106-130,2006.
TOKARSKA-SCHLATTNER, M.; ZAUGG, M.; ZUPPINGER, C.; WALLIMANN, T.; SCHLATTNER, U. New insights into doxorubicin-induced cardiotoxicity: The critical role of cellular energetics Journal of Molecular and Cellular Cardiology, v.41, n.3, p.389-405, 2006.
VARTERASIAN, M. L.; MOHAMMAD, R. M.; EILENDER, D. S.; HULBURD, K.; RODRIGUEZ, D. H.; PEMBERTON, P. A.; PLUDA, J. M.; DAN, M. D.; PETTIT, G. R.; CHEN, B. D.; AL-KATIB, A. M. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin’s lymphoma and chronic lymphocytic leukemia Journal of Clinical Oncology, v.16, n.1, p.56-62, 1998.
VELDHUIZEN, P. J. V.; FAULKNER, J. R.; LARAJR. P. N.; GUMERLOCK, P. H.; GOODWIN, J. W.; DAKHIL, S. R.; GROSS, H. M.; FLANIGAN R. C.;CRAWFORD E. D. Resistance to endocrine therapy in breast cancer. Cancer Chemotherapy and
Pharmacology, v.56, p.39-46, 2005.
VENKAT, R.; MACHERLA, S. M.; RAMA RAO MANAM, R. R.; REED, K. A.; CHAO, T.; NICHOLSON, B.; DEYANAT-YAZDI, G. Structure-Activity Relationship Studies of Salinosporamide A (NPI-0052), a Novel Marine Derived Proteasome Inhibitor. Journal of Medicinal Chemistry, v.48, n.11, p.3684-3687, 2005.
XIE, X.; WATANABE, K.; WOJCICKI, W. A.; WANG, C. C. C.; TANG, Y. Biosynthesis of Lovastatin Analogs with a Broadly Specific Acyltransferase. Chemistry & Biology, v.13, n.11, p.1161-1169, 2006.
WHO: WORLD HEALTH ORGANIZATION. http://www.who.int/mediacentre/factsheets/
fs297/en/index.html; Acessado em 15/04/2007.
ZANGARI, M.; CAVALLO, F.; TRICOT, G. Farnesyltransferase Inhibitors and Rapamycin in the Treatment of Multiple Myeloma. Current Pharmaceutical Biotechnology, v.7, n.6, p.449-453, 2006.

Artigos mais lidos pelo mesmo(s) autor(es)

A. C. Pinheiro, M. L. F. Bispo, M. V. N. Souza, A Importância do Núcleo Quinolínico e seus Derivados no Desenvolvimento de Fármacos. , Revista Fitos: v. 5 n. 03 (2010)
M. V. N. Souza, R. S. B. Gonçalves, M. B. Barreto, C. R. B. Gomes, Produtos Naturais Inibidores da Transcriptase Reversa do Vírus HIV , Revista Fitos: v. 4 n. 01 (2009)
M. V. N. De Souza, R. S. B. Gonçalves, M. L. Ferreira, M. T. Ventura, M. A. Peralta, Triterpenos como Inibidores de Fusão: Uma Nova Estratégia no Combate ao Vírus HIV , Revista Fitos: v. 2 n. 03 (2006)

PDF

HTML

Salvar em favoritos

Autor(es)

M. V. N. Souza
Instituto de Tecnologia em Fármacos, Far Manguinhos, Fundação Oswaldo Cruz Rua Sizenando Nabuco 100, Manguinhos, 21041-250 Rio de Janeiro, RJ, Brasil
A. C. Pinheiro
Instituto de Tecnologia em Fármacos, Far Manguinhos, Fundação Oswaldo Cruz Rua Sizenando Nabuco 100, Manguinhos, 21041-250 Rio de Janeiro, RJ, Brasil Instituto de Química, Universidade Federal do Rio de Janeiro Av. Brigadeiro Tromposwski s/n, CT, Bloco A, sala 605 Cidade Universitária, Ilha do Fundão, 21941590 Rio de Janeiro, RJ, Brasil
M. L. Ferreira
Instituto de Tecnologia em Fármacos, Far Manguinhos, Fundação Oswaldo Cruz Rua Sizenando Nabuco 100, Manguinhos, 21041-250 Rio de Janeiro, RJ, Brasil Centro de Estudos Gerais, Instituto de Química, Universidade Federal Fluminense, Campus do Valonguinho s/n, Centro, 24020-150 Niteroi, RJ, Brasil
R. S. B. Gonçalves
Instituto de Tecnologia em Fármacos, Far Manguinhos, Fundação Oswaldo Cruz Rua Sizenando Nabuco 100, Manguinhos, 21041-250 Rio de Janeiro, RJ, Brasil Instituto de Química, Universidade Federal do Rio de Janeiro Av. Brigadeiro Tromposwski s/n, CT, Bloco A, sala 605 Cidade Universitária, Ilha do Fundão, 21941590 Rio de Janeiro, RJ, Brasil
Camilo H. da C. Lima
Instituto de Tecnologia em Fármacos, Far Manguinhos, Fundação Oswaldo Cruz Rua Sizenando Nabuco 100, Manguinhos, 21041-250 Rio de Janeiro, RJ, Brasil Centro de Estudos Gerais, Instituto de Química, Universidade Federal Fluminense, Campus do Valonguinho s/n, Centro, 24020-150 Niteroi, RJ, Brasil

Métricas

Artigo visto 1002 vez(es)

Como Citar

Produtos Naturais em Fase Avançada de Testes Clínicos no Tratamento contra o Câncer. Rev Fitos [Internet]. 1º de junho de 2007 [citado 21º de novembro de 2024];3(02):25-42. Disponível em: https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/72

Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.

[1] AHN, Y. M.; VOGETI, L.; LIU, C.; SANTHAPURAM, H. K. R.; WHITE, J. M.; VASANDANI, V.; MITSCHER, L. A.; LUSHINGTON, G. H.; HANSON, P. R.; POWELL, D. R.; HIMES, R. H.; ROBY, K. F.; YE, Q.; GEORG, G. Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues. Bioorganic & Medicinal Chemistry, v.15, n.2, p.702-713, 2007.

[2] ALBERTS, B.; BRAY, D.; LEWIS, J.; RAFF, M.; ROBERTS, K.; WATSON, J. D. Molecular biology of the cell, Garland Publishing; New York & London; 1994.

[3] ALBERTS, M. W.; WILLIAMS, R.T.; BROWN, E. J.; TANAKA, A.; HALL, F. L.; SCHREIBER, S. L. FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line. Journal of Biological chemistry, v.268, n.30, p.22825-22829, 1993.

[4] ALCARO, S.; MARINO, T.; ORTUSO, F.; RUSSO, N. Conformational behavior of antineoplastic peptides Dolastatin 10 and Dolastatin 15 from Monte Carlo and molecular dynamics simulations. International Journal of Quantum Chemistry, v.107, n.2, p.318-325, 2007.

[5] BAI, X.C.; LIU, AN-LING, LUO, SHEN-QIU. Phospholipase C is required for survival in heat stress: involvement of protein kinase C-dependent Bcl-2 phosphorylation. Journal of Biochemistry, v.131, n.2, p.207-212, 2002.

[6] BAGATELL, R.; BELIAKOFF, J.; DAVID, C. L.; MARRON, M. T.; WHITESELL, L. Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin. International Journal of Cancer, v.113, n.2, p.179-188, 2005.

[7] BEDIN, M.; GABEN, A. M.; SAUCIER, C.; MESTER, J. Geldanamycin, an inhibitor of the chaperone activity of HSP90, induces MAPK-independent cell cycle arrest. International Journal of Cancer, v.109, n.5, p.643-652, 2004.

[8] BERGMANN, W.; BURKE, D. C. Contributions to the study of marine products. The nucleosides of sponges. Journal of Organic Chemistry, v.20, n.11, p.1501-1507, 1955.

[9] BEUMER, J. H.; RADEMAKER-LAKHAI, J. M.; ROSING, H.; HILLEBRAND, M. J. X.; BOSCH, T. M.; LAZARO, L. L.; SCHELLENS, J. H. M.; BEIJNEN, J. H. Metabolism of trabectedin (ET-743, Yondelisâ„¢) in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, v.59, n.6, p.825-837, 2007.

[10] BRANDON, E. F. A.; SPARIDANS, R. W.; OOIJEN, R. D.; MEIJERMAN, I.; LAZARO, L. L.; MANZANARES, I.; BEIJNEN, J. H.; SCHELLENS, J. H. M. In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anticancer drug. Investigational New Drugs, v.25, n.1, p.9-19, 2007.

[11] CHEN, X.; CHEN, J.; ZHU, J. Synthetic studies on ecteinascidin 743 (Et 743): asymmetric synthesis of a highly oxygenated tetrahydroisoquinoline via a key phenolic Mannich reaction. Synthesis, n.23, p.4081-4086, 2006.

[12] CALABRESI, P.; CHABNER, B. A. Chemotherapy of neoplasic diseases, Em Goodman e Gilman´s: the pharmacological basis of therapeutical, MacGraw-Hill; New York; 2001.

[13] CAUBERT, V.; MASSE, J.; RETAILLEAU, P.; LANGLOIS, N. Stereoselective formal synthesis of the potent proteasome inhibitor: salinosporamide A. Tetrahedron Letters, v.48, n.3, p.381-384, 2007.

[14] CHEN, W.; SHAO, X.; MOELLERING, R.; WENNERSTEN, C.; REGEN, S. L.; Bioconjugate Chemistry, v.17, n.6, p.1582-1591, 2006.

[15] CHLADE-BARTUSIAK, K.; STEMBALSKA-KOZLOWSKA, A.; BERNADY, M.; KUDYBA, M.; SASIADEK, M. Analysis of adaptive response to bleomycin and mitomycin. Mutation Research, Genetic Toxicology and Environmental Mutagenesis, v.513, n.1, p.75-81, 2002.

[16] CHO, J. J.; KIM, Y. T. Sharks: A Potential Source of Antiangiogenic Factors and Tumor Treatments. Marine Biotechnology, v.4, n.6, p.521-525, 2002.

[17] CRAGG, G. M.; NEWMAN, D. J. A Tale of Two Tumor Targets: Topoisomerase I and Tubulin. The Wall and Wani Contribution to Cancer Chemotherapy. Journal of Natural Products, v.67, n.2, p.232-244, 2004.

[18] CUENDET, M.; PEZZUTO, J. M. Antitumor Activity of Bruceantin: An Old Drug with New Promise. Journal of Natural Products, v.67, n.2, p.269-272, 2004.

[19] DE VITA JR., V. T.; HELLMAN, S.; ROSENBERG, S. A. Cancer: Principles of Oncology, LippincottRaven Publishers; Phifadelphia, 1997.

[20] DONIA, M.; HAMANN, M. T. Marine natural products and their potential applications as anti-infective agents. Lancet Infectious Diseases, v.3, n.6, p.338-348, 2003.

[21] ERBA, E.; BASSANO, L.; DI LIBERTI, G. Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine. British Journal of Cancer, v.86, n.9, p.1510-1517, 2002.

[22] ERBA, E.; BERGAMASCHI, D.; BASSANO, L. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. European Journal of Cancer, v.37, n.1, p.97-105, 2001.

[23] GARCÍA-FERNÁNDEZ, L.F.; LOSADA, A.; ALCALDE, V. Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C. Oncogene, v.21, n.49, p.7533-7544, 2002.

[24] GARCIA, C. R.; SUPKO, J.G.; MANOLA, J. Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy. Journal of Clinical Oncology, v.22, n.8, p.1480-1490, 2004.

[25] GRACIA, C.; ISIDRO-LLOBET, A.; CRUZ, L. J.; ACOSTA, G. A.; ALVAREZ, M.; CUEVAS, C.; GIRALT, E.; ALBERICIO, F. Convergent Approaches for the Synthesis of the Antitumoral Peptide, Kahalalide F. Study of Orthogonal Protecting Groups. Journal of Organic Chemistry, v.71, n.19, p.7196-7204, 2006.

[26] GSCHWEND, J.E. Bryostatin 1 induces prolonged activation of extracellular regulated protein kinases in and apoptosis of LNCaP human prostate cancer cells overexpressing protein kinase C. Molecular Pharmacology, v.57, n.6, p.1224-1234, 2000.

[27] HITOTSUYANAGI, Y.; KIM, I. H.; HASUDA, T.; YAMAUCHI, Y.; TAKEYA, K. A structure-activity relationship study of brusatol, an antitumor quassinoid. Tetrahedron, v.62, n.17, p.4262-4271, 2006.

[28] INCA: Instituto Nacional de Câncer. http://www.inca.gov.br/situacao/arquivos/ocorrencia_magnitude_cancerbrasil.pdf; Acessado em 15/04/2007a.

[29] INCA: Instituto Nacional de Câncer. http://www.inca.gov.br/conteudo_view.asp?id=101, Acessado em 15/04/2007b.

[30] JULSING, M. K.; KOULMAN, A.; WOERDENBAG, H. J.; QUAX, W. J.; KAYSER, O. Combinatorial biosynthesis of medicinal plant secondary metabolites. Biomolecular Engineering, v.23, n.6, p.265-279, 2006.

[31] KECK, G. E.; WELCH, D. S.; POUDEL, Y. B. Synthetic studies toward bryostatin 1: preparation of a C1-C16 fragment by pyran annulation. Tetrahedron Letters, v.47, n.47, p.8267-8270, 2006.

[32] KLINDLEN, H. L. Phase II study of flavopiridol in patients with advanced colorectal cancer. Annals of Oncology, v.14, p.1270-1273, 2003.

[33] KOUROUKIS, C. T.; BELCH, A.; CRUMP, M.; EISENHAUER, E.; GASCOYNE, R. D.; MEYER, R.; LOHMANN, R.; LOPEZ, P.; POWERS, J.; TURNER, R.; CONNORS, J. M. Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, v.21, n.9, p.1740-1745, 2003.

[34] KUPCHAN, S. M.; BRITTON, R. W.; ZIEGLER, M. F.; SIGEL, C. W. Bruceantin, a new potent anti- leukemic simaroubolide from Brucea antidysenterica. Journal of Organic Chemistry,v.38, n.1, p.178-179, 1973.

[35] LE CESNE, L.; BLAY, J.Y.; JUDSON, I. Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organization for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial. Journal of Clinical Oncology, v.23, n.3, p.576-584, 2005.

[36] LIN, C. M. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Molecular Pharmacology, v.34, n.2, p.200-208, 1988.

[37] MADDEN, T.; TRAN, H. T.; BECK, D.; HUIE, R.; NEWMAN, R. A.; PUSZTAI, L.; WRIGHT, J. J.; ABBRUZZESE, J. L. Novel Marine-derived Anticancer Agents: A Phase I Clinical, Pharmacological, and Pharmacodynamic Study of Dolastatin 10 (NSC 376128) in Patients with Advanced Solid Tumors. Clinical Cancer Research, v.6, n.4, p.1293-1301, 2000.

[38] MANN, J. Natural products in cancer chemotherapy: past, present and future. Nature Reviews Cancer, v.2, n.2, 143-148, 2002.

[39] MINUZZO, M.; MARCHINI, S.; BROGGINI, M.; FAIRCLOTH, G.T.; D’INCALCI, M.; MANTOVANI, R. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proceedings of the National Academy of Sciences of the United States of America, v.97, n.12, p. 6780-6784, 2000.

[40] NERI, B.; PANTALEO, P.; GIOMMONI, E.; GRIFONI, R.; PAOLETTI, C.; ROTELLA, V.; PANTALONE, D.; TADDEI, A.; MERCATELLI, A.; TONELLI, P. Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study. British Journal of Cancer, v.96, p.1043-1046, 2007.

[41] NEWMAN, D. J.; CRAGG, G. M.; SNADER, K. M. Natural Products as Sources of New Drugs over the Period 1981-2002. Journal of Natural Products, v.66, n.7, p.1022-1037, 2003.

[42] NOVAK, N.; GERDIN, S.; BEROVIC, M. Increased lovastatin formation by Aspergillus terreus using repeated fed-batch process. Biotechnology Letters, v.19, n.10, p.947-948, 1997.

[43] POMMIER, Y. Topoisomerase I inhibitors: camptothecins and beyond. Nature Reviews Cancer, v.6, n.10, p.789-802, 2006.

[44] RADEMAKER-LAKHAI, J.; HORENBLAS, S.; MEINHARDT, W. Phase I Clinical and Pharmacokinetic Study of Kahalalide F in Patients with Advanced Androgen Refractory Prostate Cancer. Clinical Cancer Research, v.11, n.5, p.1854-1862, 2005.

[45] RITU, B.; UMA, S.; NANDANA, S.; MONICA, J.; PAMITA, A.; MANPREET, K.; KUMAR, B. S.; GIRJESH, G. Structure of daunomycin complexed to dTGATCA by two-dimensional nuclear magnetic resonance spectroscopy. European Journal of Medicinal Chemistry, v.41, n.1, p.27-39, 2006.

[46] ROBERT, H.; FELING, G. O.; BUCHANAN, T. J.; MINCER, C. A.; KAUFFMAN, P. R.; FENICAL, W. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angewandte Chemie, International Edition, v.42, n.3, p.355-357, 2003.

[47] ROCHA, A. B.; LOPES, R. M.; SCHWARTSMANN, G. Natural products in anticancer therapy. Current Opinion in Pharmacology, v.1, n.4, p. 364-369,

[49] SCHULTE, T. W.; NECKERS, L. M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemotherapy and Pharmacology, v.42, n.4, p.273-279, 1998.

[50] SENDEROWICZ, A. M. Flavopiridol: the First Cyclin-Dependent Kinase Inhibitor in Human Clinical Trials. Investigational New Drugs, v.17, n.3,

[51] p.313-320, 1999.

[52] SOLAR, P.; HORVATH, V.; KLEBAN, J.; KOVAL, J.; SOLAROVA, Z.; KOZUBIK, A.; FEODOROCKO, P. Hsp90 inhibitor Geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin. Neoplasma, v.54, n.2, p.127-130, 2007.

[53] SPANO, A.; MONACO, G.; BARNI, S.; SCIOLA, L. Expression of cell kinetics and death during monocyte-macrophage differentiation: Effects of actinomycin D and vinblastine treatments. Histochemistry and Cell Biology, v.127, n.1, p.79-94, 2007.

[54] SOUZA, M. V. N. New natural products able to act on the stabilization of microtubules, an important target against cancer. Química Nova, v.27,

[55] n.2, p.308-312, 2004.

[56] STROSBERG, J. R.; KVOLS, L. K. A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours. Expert Opinion on Investigational Drugs, v.16, n.2, p.219-224, 2007.

[57] SUN, M.; ALKON, D. L. Bryostatin-1: Pharmacology and Therapeutic Potential as a CNS Drug. CNS Drug Reviews, v.12, n.1, p.1-8, 2006.

[58] TEDESCHI, A.; MONTILLO, M.; STROCCHI, E.; CAFRO, A. M.; TRESOLDI, E.; INTROPIDO, L.; NICHELATTI, M.; MARBELLO, L.; BARATE, C.; CAMAGGI, C. M.; MORRA, E. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Cancer Chemotherapy and Pharmacology, v.59, n.6, p.771-779, 2007.

[59] THUN, M. J.; JEMAL, A.; SIEGEL, R.; WARD, E.; MURRAY, T.; XU, J.; SMIGAL, C. Cancer Statistics. CA-A Cancer Journal for Clinicians, v.56, n.2, p.106-130,2006.

[60] TOKARSKA-SCHLATTNER, M.; ZAUGG, M.; ZUPPINGER, C.; WALLIMANN, T.; SCHLATTNER, U. New insights into doxorubicin-induced cardiotoxicity: The critical role of cellular energetics Journal of Molecular and Cellular Cardiology, v.41, n.3, p.389-405, 2006.

[61] VARTERASIAN, M. L.; MOHAMMAD, R. M.; EILENDER, D. S.; HULBURD, K.; RODRIGUEZ, D. H.; PEMBERTON, P. A.; PLUDA, J. M.; DAN, M. D.; PETTIT, G. R.; CHEN, B. D.; AL-KATIB, A. M. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin’s lymphoma and chronic lymphocytic leukemia Journal of Clinical Oncology, v.16, n.1, p.56-62, 1998.

[62] VELDHUIZEN, P. J. V.; FAULKNER, J. R.; LARAJR. P. N.; GUMERLOCK, P. H.; GOODWIN, J. W.; DAKHIL, S. R.; GROSS, H. M.; FLANIGAN R. C.;CRAWFORD E. D. Resistance to endocrine therapy in breast cancer. Cancer Chemotherapy and

[63] Pharmacology, v.56, p.39-46, 2005.

[64] VENKAT, R.; MACHERLA, S. M.; RAMA RAO MANAM, R. R.; REED, K. A.; CHAO, T.; NICHOLSON, B.; DEYANAT-YAZDI, G. Structure-Activity Relationship Studies of Salinosporamide A (NPI-0052), a Novel Marine Derived Proteasome Inhibitor. Journal of Medicinal Chemistry, v.48, n.11, p.3684-3687, 2005.

[65] XIE, X.; WATANABE, K.; WOJCICKI, W. A.; WANG, C. C. C.; TANG, Y. Biosynthesis of Lovastatin Analogs with a Broadly Specific Acyltransferase. Chemistry & Biology, v.13, n.11, p.1161-1169, 2006.

[66] WHO: WORLD HEALTH ORGANIZATION. http://www.who.int/mediacentre/factsheets/

[67] fs297/en/index.html; Acessado em 15/04/2007.

[68] ZANGARI, M.; CAVALLO, F.; TRICOT, G. Farnesyltransferase Inhibitors and Rapamycin in the Treatment of Multiple Myeloma. Current Pharmaceutical Biotechnology, v.7, n.6, p.449-453, 2006.